Allogene Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing genetically engineered allogeneic T cell therapies for cancer treatment. The core product of the company is UCART19, an allogeneic chimeric antigen receptor T cell product candidate, being developed for the treatment of B-cell acute lymphoblastic leukemia. The company is also developing CAR T cells product candidates for the treatment of other blood cancers and solid tumors.